Select the β-adrenergic blocker that has additional α1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Select the β-adrenergic blocker that has additional α1
blocking, vasodilator and antioxidant properties:
A. Carvedilol
B. Celiprolol
C. Acebutolol
D. Metoprolol
by

1 Answer

Answer :

A. Carvedilol
by

Related questions

Select the β -adrenergic blocker that has additional α 1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Description : Select the β -adrenergic blocker that has additional α 1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Last Answer : A. Carvedilol

The β adrenergic blocker having β1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Description : The β adrenergic blocker having β1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Last Answer : C. Acebutolol

The β adrenergic blocker having β 1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Description : The β adrenergic blocker having β 1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Last Answer : C. Acebutolol

The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally blocks α1 and α2 adrenoceptors C. It is the most potent α blocker D. It has no additional β adrenergic blocking property

Description : The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally ... It is the most potent α blocker D. It has no additional β adrenergic blocking property

Last Answer : A. It produces rapid and short lasting α-adrenergic blockade

The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally blocks α1 and α2 adrenoceptors C. It is the most potent α blocker D. It has no additional β adrenergic blocking property

Description : The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally ... It is the most potent α blocker D. It has no additional β adrenergic blocking property

Last Answer : A. It produces rapid and short lasting α-adrenergic blockade

Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Description : Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Last Answer : D. Atenolol

Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Description : Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Last Answer : D. Atenolol

Select the ultrashort acting cardioselective β adrenergic blocker: A. Bisoprolol B. Timolol C. Sotalol D. Esmolol

Description : Select the ultrashort acting cardioselective β adrenergic blocker: A. Bisoprolol B. Timolol C. Sotalol D. Esmolol

Last Answer : D. Esmolol

Select the ultrashort acting cardioselective β adrenergic blocker: A. Bisoprolol B. Timolol C. Sotalol D. Esmolol

Description : Select the ultrashort acting cardioselective β adrenergic blocker: A. Bisoprolol B. Timolol C. Sotalol D. Esmolol

Last Answer : D. Esmolol

The ß-adrenergic blocker which possesses both ß1 selectivity as well as intrinsic sympathomimetic activity is (a) Alprenolol (b) Atenolol (c) Acebutolol (d) Metoprolol

Description : The ß-adrenergic blocker which possesses both ß1 selectivity as well as intrinsic sympathomimetic activity is (a) Alprenolol (b) Atenolol (c) Acebutolol (d) Metoprolol

Last Answer : Ans: C

The following is true of propafenone except: A. It is a weak Na+ channel blocker B. It markedly delays recovery of myocardial Na+ channels C. It has additional β-adrenergic blocking property D. It slows anterograde as well as retrograde conduction in the WPW bypass tract

Description : The following is true of propafenone except: A. It is a weak Na+ channel blocker B. It markedly delays recovery of myocardial Na+ channels C. It has additional β-adrenergic blocking property D. It slows anterograde as well as retrograde conduction in the WPW bypass tract

Last Answer : A. It is a weak Na+ channel blocker

The bladder trigone and prostatic muscles are relaxed by: A. Adrenergic α1 agonists B. Adrenergic α1 antagonists C. Adrenergic α2 agonists D. Adrenergic α2 antagonists

Description : The bladder trigone and prostatic muscles are relaxed by: A. Adrenergic α1 agonists B. Adrenergic α1 antagonists C. Adrenergic α2 agonists D. Adrenergic α2 antagonists

Last Answer : B. Adrenergic α1 antagonists

Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Description : Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Last Answer : D. α2 receptor

Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Description : Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Last Answer : A. It has additional α1 blocking property

Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Description : Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Last Answer : A. It has additional α1 blocking property

The drug which produces vasoconstriction despite being an α adrenergic blocker is: A. Phenoxybenzamine B. Ergotamine C. Dihydroergotoxine D. Tolazoline

Description : The drug which produces vasoconstriction despite being an α adrenergic blocker is: A. Phenoxybenzamine B. Ergotamine C. Dihydroergotoxine D. Tolazoline

Last Answer : B. Ergotamine

Beta adrenergic blockers lower intraocular tension by: A. Down regulating adenylyl cyclase in ciliary body through reduced activation of β2 adrenoceptors B. Constricting ciliary blood vessels C. Blocking adrenergic action on trabecular meshwork D. Reducing aqueous formation unrelated to beta adrenoceptor mediation

Description : Beta adrenergic blockers lower intraocular tension by: A. Down regulating adenylyl cyclase in ciliary body through reduced activation of β2 adrenoceptors B. Constricting ciliary blood vessels ... action on trabecular meshwork D. Reducing aqueous formation unrelated to beta adrenoceptor mediation

Last Answer : A. Down regulating adenylyl cyclase in ciliary body through reduced activation of β2 adrenoceptors

In hyperthyroidism, β adrenergic blockers are used: A. To induce euthyroid state B. As definitive therapy C. For rapid control of certain symptoms while awaiting response to carbimazole D. To reduce basal metabolic rate

Description : Select the β-adrenergic blocker that has additional α1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Last Answer : C. Acebutolol

In a patient of myocardial infarction, β adrenergic blockers are used with the following aim/aims: A. To reduce the incidence of reinfarction B. To prevent cardiac arrhythmias C. To limit size of the infarct D. All of the above

Description : In a patient of myocardial infarction, β adrenergic blockers are used with the following aim/aims: A. To reduce the incidence of reinfarction B. To prevent cardiac arrhythmias C. To limit size of the infarct D. All of the above

Last Answer : D. All of the above

Esmolol has the following features except: A. Rapidly developing, shortlasting β adrenergic blockade B. Cardioselectivity of action C. Intrinsic sympathomimetic activity D. Suitability for intraoperative use

Description : Esmolol has the following features except: A. Rapidly developing, shortlasting β adrenergic blockade B. Cardioselectivity of action C. Intrinsic sympathomimetic activity D. Suitability for intraoperative use

Last Answer : C. Intrinsic sympathomimetic activity

β-adrenergic blockers are indicated in the following conditions except: A. Hypertrophic cardiomyopathy B. Congestive heart failure C. Vasospastic angina pectoris D. Dissecting aortic aneurysm

Description : β-adrenergic blockers are indicated in the following conditions except: A. Hypertrophic cardiomyopathy B. Congestive heart failure C. Vasospastic angina pectoris D. Dissecting aortic aneurysm

Last Answer : C. Vasospastic angina pectoris

Sildenafil is contraindicated in patients taking the following class of drugs: A. α-adrenergic blockers B. β-adrenergic blockers C. Organic nitrates D. Angiotensin converting enzyme inhibitors

Description : Sildenafil is contraindicated in patients taking the following class of drugs: A. α-adrenergic blockers B. β-adrenergic blockers C. Organic nitrates D. Angiotensin converting enzyme inhibitors

Last Answer : C. Organic nitrates

Ephedrine is similar to adrenaline in the following feature: A. Potency B. Inability to penetrate blood-brain barrier C. Duration of action D. Producing both α and β adrenergic effects

Description : Ephedrine is similar to adrenaline in the following feature: A. Potency B. Inability to penetrate blood-brain barrier C. Duration of action D. Producing both α and β adrenergic effects

Last Answer : D. Producing both α and β adrenergic effects

Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Description : Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Last Answer : A. It does not activate peripheral dopaminergic receptors

In hyperthyroidism, β adrenergic blockers are used: A. To induce euthyroid state B. As definitive therapy C. For rapid control of certain symptoms while awaiting response to carbimazole D. To reduce basal metabolic rate

Description : In hyperthyroidism, β adrenergic blockers are used: A. To induce euthyroid state B. As definitive therapy C. For rapid control of certain symptoms while awaiting response to carbimazole D. To reduce basal metabolic rate

Last Answer : C. For rapid control of certain symptoms while awaiting response to carbimazole

Esmolol has the following features except: A. Rapidly developing, shortlasting β adrenergic blockade B. Cardioselectivity of action C. Intrinsic sympathomimetic activity D. Suitability for intraoperative use

Description : Esmolol has the following features except: A. Rapidly developing, shortlasting β adrenergic blockade B. Cardioselectivity of action C. Intrinsic sympathomimetic activity D. Suitability for intraoperative use

Last Answer : C. Intrinsic sympathomimetic activity

β -adrenergic blockers are indicated in the following conditions except: A. Hypertrophic cardiomyopathy B. Congestive heart failure C. Vasospastic angina pectoris D. Dissecting aortic aneurysm

Description : β -adrenergic blockers are indicated in the following conditions except: A. Hypertrophic cardiomyopathy B. Congestive heart failure C. Vasospastic angina pectoris D. Dissecting aortic aneurysm

Last Answer : C. Vasospastic angina pectoris

Sildenafil is contraindicated in patients taking the following class of drugs: A. α-adrenergic blockers B. β-adrenergic blockers C. Organic nitrates D. Angiotensin converting enzyme inhibitors

Description : Sildenafil is contraindicated in patients taking the following class of drugs: A. α-adrenergic blockers B. β-adrenergic blockers C. Organic nitrates D. Angiotensin converting enzyme inhibitors

Last Answer : C. Organic nitrates

Ephedrine is similar to adrenaline in the following feature: A. Potency B. Inability to penetrate blood-brain barrier C. Duration of action D. Producing both α and β adrenergic effects

Description : Ephedrine is similar to adrenaline in the following feature: A. Potency B. Inability to penetrate blood-brain barrier C. Duration of action D. Producing both α and β adrenergic effects

Last Answer : D. Producing both α and β adrenergic effects

Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β 1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Description : Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β 1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Last Answer : B. Dobutamine

Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Description : Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Last Answer : A. It does not activate peripheral dopaminergic receptors

Dopaminergic D1 and D2 as well as adrenergic α and β 1, but not β 2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Description : Dopaminergic D1 and D2 as well as adrenergic α and β 1, but not β 2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Last Answer : A. Dopamine

The quarternary analogues of belladonna alkaloids are preferred over the natural alkaloids for antisecretory/ antispasmodic indications because: A. They have additional nicotinic receptor blocking activity B. They are incompletely absorbed after oral administration C. They are devoid of CNS and ocular effects D. Dose to dose they are more potent than atropine

Description : The quarternary analogues of belladonna alkaloids are preferred over the natural alkaloids for antisecretory/ antispasmodic indications because: A. They have additional nicotinic receptor blocking activity B. They are ... of CNS and ocular effects D. Dose to dose they are more potent than atropine

Last Answer : C. They are devoid of CNS and ocular effects

To be used as a topically applied ocular beta blocker a drug should have the following properties except: A. Strong local anaesthetic activity B. High lipophilicity C. High ocular capture D. Low systemic activity

Description : To be used as a topically applied ocular beta blocker a drug should have the following properties except: A. Strong local anaesthetic activity B. High lipophilicity C. High ocular capture D. Low systemic activity

Last Answer : A. Strong local anaesthetic activity

Select the longer acting ocular beta blocker: A. Timolol B. Betaxolol C. Cartiolol D. Levobunolol

Description : Select the longer acting ocular beta blocker: A. Timolol B. Betaxolol C. Cartiolol D. Levobunolol

Last Answer : D. Levobunolol

A drug lacking vasodilator properties that is useful in angina is (a) Isosorbide dinitrate (b) Metoprolol (c) NIfedipine (d) Nitroglycerin (e) Verapamil

Description : A drug lacking vasodilator properties that is useful in angina is (a) Isosorbide dinitrate (b) Metoprolol (c) NIfedipine (d) Nitroglycerin (e) Verapamil

Last Answer : Ans: B

The following sympathomimetic amine has agonistic action on α1 + α2 + β1 + β3 adrenoceptors, but not on β2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Description : The following sympathomimetic amine has agonistic action on α1 + α2 + β1 + β3 adrenoceptors, but not on β2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Last Answer : B. Noradrenaline

Low dose therapy with the following category of antihypertensive drugs has been found to be more advantageous in the long-term than high dose therapy with the same drugs: A. β adrenergic blockers B. α1 adrenergic blockers C. Central sympatholytics D. Diuretics

Description : Low dose therapy with the following category of antihypertensive drugs has been found to be more advantageous in the long-term than high dose therapy with the same drugs: A. β adrenergic blockers B. α1 adrenergic blockers C. Central sympatholytics D. Diuretics

Last Answer : D. Diuretics

Which of the following is a selective α1A receptor blocker that affords symptomatic relief in benign prostatic hypertrophy without producing significant fall in blood pressure: A. Terazosin B. Doxazosin C. Trimazosin D. Tamsulosin

Description : Which of the following is a selective α1A receptor blocker that affords symptomatic relief in benign prostatic hypertrophy without producing significant fall in blood pressure: A. Terazosin B. Doxazosin C. Trimazosin D. Tamsulosin

Last Answer : D. Tamsulosin

Betaxolol differs from timolol in that it: A. Is a β1 selective blocker B. Is more efficacious in glaucoma C. Produces less ocular side effects D. Is longer acting

Description : Betaxolol differs from timolol in that it: A. Is a β1 selective blocker B. Is more efficacious in glaucoma C. Produces less ocular side effects D. Is longer acting

Last Answer : A. Is a β1 selective blocker

Which of the following is a selective α 1A receptor blocker that affords symptomatic relief in benign prostatic hypertrophy without producing significant fall in blood pressure: A. Terazosin B. Doxazosin C. Trimazosin D. Tamsulosin

Description : Which of the following is a selective α 1A receptor blocker that affords symptomatic relief in benign prostatic hypertrophy without producing significant fall in blood pressure: A. Terazosin B. Doxazosin C. Trimazosin D. Tamsulosin

Last Answer : D. Tamsulosin

Tetrodotoxin blocks nerve impulse/junctional transmission by: A. Anticholinergic action B. Depleting acetylcholine C. Blocking Na+ channels D. Blocking Ca2+ channels

Description : Tetrodotoxin blocks nerve impulse/junctional transmission by: A. Anticholinergic action B. Depleting acetylcholine C. Blocking Na+ channels D. Blocking Ca2+ channels

Last Answer : C. Blocking Na+ channels

Tetrodotoxin blocks nerve impulse/junctional transmission by: A. Anticholinergic action B. Depleting acetylcholine C. Blocking Na+ channels D. Blocking Ca2+ channels

Description : Tetrodotoxin blocks nerve impulse/junctional transmission by: A. Anticholinergic action B. Depleting acetylcholine C. Blocking Na+ channels D. Blocking Ca2+ channels

Last Answer : C. Blocking Na+ channels

The nonselective α adrenergic blockers produce the following actions except: A. Postural hypotension B. Bradycardia C. Miosis D. Inhibition of ejaculation

Description : The nonselective α adrenergic blockers produce the following actions except: A. Postural hypotension B. Bradycardia C. Miosis D. Inhibition of ejaculation

Last Answer : B. Bradycardia

Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Description : Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Last Answer : B. Dobutamine

Dopaminergic D1 and D2 as well as adrenergic α and β1, but not β2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Description : Dopaminergic D1 and D2 as well as adrenergic α and β1, but not β2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Last Answer : A. Dopamine

The principal process which terminates the action of noradrenaline released from adrenergic nerve ending is: A. Degradation by MAO B. Methylation by COMT C. Axonal uptake D. Extraneuronal uptake

Description : The principal process which terminates the action of noradrenaline released from adrenergic nerve ending is: A. Degradation by MAO B. Methylation by COMT C. Axonal uptake D. Extraneuronal uptake

Last Answer : C. Axonal uptake

Tyramine induces release of noradrenaline from adrenergic nerve endings: A. By depolarizing the axonal membrane B. By mobilizing Ca2+ C. By a nonexocytotic process D. Only in the presence of MAO inhibitors

Description : Tyramine induces release of noradrenaline from adrenergic nerve endings: A. By depolarizing the axonal membrane B. By mobilizing Ca2+ C. By a nonexocytotic process D. Only in the presence of MAO inhibitors

Last Answer : C. By a nonexocytotic process

The following is true of β-adrenergic blocker therapy in CHF: A. They are added to conventional therapy after cardiac compensation is restored B. They are indicated only in severe (NYHA class IV) heart failure C. They are to be used only at low doses D. All of the above

Description : The following is true of β-adrenergic blocker therapy in CHF: A. They are added to conventional therapy after cardiac compensation is restored B. They are indicated only in severe (NYHA class IV) heart failure C. They are to be used only at low doses D. All of the above

Last Answer : A. They are added to conventional therapy after cardiac compensation is restored

Labetalol has: A. More potent β adrenergic blocking than α blocking activity B. More potent α adrenergic blocking than β blocking activity C. Equal α and β adrenergic blocking activity D. β1 agonistic activity in addition to α and β adrenergic blockade

Description : Labetalol has: A. More potent β adrenergic blocking than α blocking activity B. More potent α adrenergic blocking than β blocking activity C. Equal α and β adrenergic blocking activity D. β1 agonistic activity in addition to α and β adrenergic blockade

Last Answer : A. More potent β adrenergic blocking than α blocking activity